
Title:
Lisinopril
Text:
Medication used to treat high blood pressure and heart failure


.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}body.skin-minerva .mw-parser-output .infobox-header,body.skin-minerva .mw-parser-output .infobox-subheader,body.skin-minerva .mw-parser-output .infobox-above,body.skin-minerva .mw-parser-output .infobox-title,body.skin-minerva .mw-parser-output .infobox-image,body.skin-minerva .mw-parser-output .infobox-full-data,body.skin-minerva .mw-parser-output .infobox-below{text-align:center}LisinoprilChemical structure of lisinoprilClinical dataPronunciation/laɪˈsɪnəprɪl/, ly-SIN-ə-pril Trade namesPrinivil,[1] Zestril,[2] Qbrelis,[3] Dapril,[4]others[5]Other names(2S)-1-[(2S)-6-amino-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}hexanoyl]pyrrolidine-2-carboxylic acidAHFS/Drugs.comMonographMedlinePlusa692051License data
EU EMA: by INN
US DailyMed: Lisinopril
US FDA: Lisinopril
Pregnancycategory
AU: D[6]
not recommended[7][6]
Routes ofadministrationBy mouthATC codeC09AA03 (WHO) C09BA03 (WHO) C10BX07 (WHO) C09BB03 (WHO)Legal statusLegal status
UK: POM (Prescription only) [8]
US: ℞-only [1][2][3]
In general: ℞ (Prescription only)
Pharmacokinetic dataBioavailabilityapprox. 25%, but wide range between individuals (6 to 60%)Protein binding0MetabolismNoneElimination half-life12 hoursExcretionEliminated unchanged in urineIdentifiersshow
IUPAC name
(2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid
CAS Number83915-83-7anhydrous: 76547-98-3 YPubChem CID5362119IUPHAR/BPS6360DrugBankDB00722 YChemSpider4514933 YUNIIE7199S1YWRanhydrous: 7Q3P4BS2FD YKEGGD00362 YChEBICHEBI:43755 NChEMBLChEMBL1237 YPDB ligandLPR (PDBe, RCSB PDB)CompTox Dashboard (EPA)DTXSID6040537 ECHA InfoCard100.071.332 Chemical and physical dataFormulaC21H31N3O5Molar mass405.495 g·mol−13D model (JSmol)Interactive imageshow
SMILES
C1CC(N(C1)C(=O)C(CCCCN)NC(CCC2=CC=CC=C2)C(=O)O)C(=O)O
show
InChI
InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1 YKey:RLAWWYSOJDYHDC-BZSNNMDCSA-N Y
.mw-parser-output .nobold{font-weight:normal} NY (what is this?)  (verify)
Lisinopril is a medication of the angiotensin-converting enzyme (ACE) inhibitor and is considered to be a gold standard drug in the treatment of  high blood pressure, and is also used to treat heart failure and after heart attacks.[7] For high blood pressure it is usually a first line treatment. It is also used to prevent kidney problems in people with diabetes mellitus.[7] Lisinopril is taken by mouth.[7] Full effect may take up to four weeks to occur.[7] Within the ACE Inhibitor class, Lisinopril has shown to have less interindividual variability within the drugs, making it a preferable choice for patients with angina and hypertension. 
Common side effects include headache, dizziness, feeling tired, cough, nausea, and rash.[7] Serious side effects may include low blood pressure, liver problems, high blood potassium, and angioedema.[7] Use is not recommended during the entire duration of pregnancy as it may harm the baby.[7] Lisinopril works by inhibiting the renin–angiotensin–aldosterone system.[7]
Lisinopril was patented in 1978 and approved for medical use in the United States in 1987.[7][9] It is available as a generic medication.[7] In 2019, it was the third most commonly prescribed medication in the United States, with more than 91 million prescriptions.[10][11] In July 2016, an oral solution formulation of lisinopril was approved for use in the United States.[7][12]

Contents

1 Structure–activity relationships
2 Medical uses

2.1 Kidney problems
2.2 Pregnancy and breastfeeding


3 Contraindications
4 Adverse effects
5 Overdose
6 Interactions

6.1 Dental care


7 Pharmacology

7.1 Mechanism of action
7.2 Pharmacokinetics

7.2.1 Absorption
7.2.2 Distribution
7.2.3 Metabolism
7.2.4 Elimination


7.3 Chemistry


8 History
9 References
10 Further reading
11 External links



Structure–activity relationships[edit]
Lisinopril has a proline group that is responsible for the availability of the drug in oral formulation. It has a carboxylate group that does not need to be metabolized, but rather interacts with Zn+2 to inhibit the ACE Enzyme found in the kidneys and lungs. For the rest of the molecule, the long carbon chain attached to the NH2, the carbonyl as well as the L-proline help to orient the molecule for attachment to the ACE Enzyme. Unlike Captopril, another drug in the same ACE Inhibitor class, Lisinopril does not have a thiol group to inhibit the ACE Enzyme, and thus reduces the likelihood of immune based adverse effects in patients as well as dysgeusia. The bulky group and long chain help the molecule's ADME profile by preventing hydrolysis by enzymes in the body.  

Medical uses[edit]
Lisinopril is typically used for the treatment of high blood pressure, congestive heart failure, and diabetic nephropathy and after acute myocardial infarction (heart attack).[7][1] Lisinopril is part of the ACE Inhibitors drug class. Compared to other drugs within the same class such as Captopril and Enalapril, Lisinopril has a longer duration of action of 24-36 hours. 
A review concluded that lisinopril was effective for treatment of proteinuric kidney disease, including diabetic proteinuria.[13]
In people of sub-Saharan African descent, calcium-channel blockers or thiazide diuretics may more effectively lower blood pressure than ACE inhibitors such as lisinopril,[7] although there is not convincing evidence that these drugs differ in their effect on morbidity or mortality in such persons.[14]

Kidney problems[edit]
In patients who have moderate to severe kidney disease, lisinopril and other ACE Inhibitors are superior to Angiotensin II receptor blockers and other antihypertensive drugs for prevention of death, fatal cardiac events, and kidney injury.[15] Dose reduction may be required when creatinine clearance is less than or equal to 30mL/min.[1] Since lisinopril is removed by dialysis, dosing changes must also be considered for people on dialysis.[1]

Pregnancy and breastfeeding[edit]
Animal and human data have revealed evidence of lethal harm to the embryo and teratogenicity associated with ACE inhibitors. No controlled data in human pregnancy are available. Birth defects have been associated with use of lisinopril in any trimester. However, there have been reports of death and increased toxicity to the fetus and newly born child with the use of lisinopril in the second and third trimesters. The label states, "When pregnancy is detected, discontinue Zestril as soon as possible." The manufacturer recommends mothers should not breastfeed while taking this medication because of the current lack of safety data.[1]

Contraindications[edit]
Lisinopril is contraindicated in people who have a history of angioedema (hereditary or idiopathic) or who have diabetes and are taking aliskiren.[1]

Adverse effects[edit]
The incidence of adverse effects varies according to which disease state the patient is being treated for.[1] 
People taking lisinopril for the treatment of hypertension may experience the following side effects:[1][failed verification]

Headache (3.8%)
Dizziness (3.5%)
Cough (2.5%) Persons with the ACE I/D genetic polymorphism may be at higher risk for ACE inhibitor-associated cough.[16]
Difficulty swallowing or breathing (signs of angioedema), allergic reaction (anaphylaxis)
Hyperkalemia (2.2% in adult clinical trials)
Fatigue (1% or more)
Diarrhea (1% or more)
Some severe skin reactions have been reported rarely, including toxic epidermal necrolysis and Stevens–Johnson syndrome; causal relationship has not been established.
People taking lisinopril for the treatment of myocardial infarction may experience the following side effects:[1][failed verification]

Hypotension (5.3%)
Kidney dysfunction (1.3%)
People taking lisinopril for the treatment of heart failure may experience the following side effects:[1][failed verification]

Hypotension (3.8%)
Dizziness (12% at low dose – 19% at high dose)
Chest pain (2.1%)
Fainting (5–7%)
Hyperkalemia (3.5% at low dose – 6.4% at high dose)
Difficulty swallowing or breathing (signs of angioedema), allergic reaction (anaphylaxis)
Fatigue (1% or more)
Diarrhea (1% or more)
Some severe skin reactions have been reported rarely, including toxic epidermal necrolysis and Stevens–Johnson syndrome; a causal relationship has not been established.
Agranulocytosis
  Lisinopril 40-mg oral tablet
Overdose[edit]
In one reported overdose, the half-life of lisinopril was prolonged to 14.9 hours.[17] The case report of the event estimates that the individual consumed between 420 and 500 mg of lisinopril and survived.[18] In cases of overdosage, it can be removed from circulation by dialysis.[1]

Interactions[edit]
Dental care[edit]
ACE-inhibitors like lisinopril are considered to be generally safe for people undergoing routine dental care, though the use of lisinopril prior to dental surgery is more controversial, with some dentists recommending discontinuation the morning of the procedure.[19] People may present to dental care suspicious of an infected tooth, but the swelling around the mouth may be due to lisinopril-induced angioedema, prompting emergency and medical referral.[19]

Pharmacology[edit]
Lisinopril is the lysine-analog of enalapril. Unlike other ACE inhibitors, it is not a prodrug, is not metabolized by the liver, and is excreted unchanged in the urine.[1]

Mechanism of action[edit]
Lisinopril is an ACE inhibitor, meaning it blocks the actions of angiotensin-converting enzyme (ACE) in the renin–angiotensin–aldosterone system (RAAS), preventing angiotensin I from being converted to angiotensin II. Angiotensin II is a potent direct vasoconstrictor and a stimulator of aldosterone release. Reduction in the amount of angiotensin II results in relaxation of the arterioles. Reduction in the amount of angiotensin II also reduces the release of aldosterone from the adrenal cortex, which allows the kidney to excrete sodium along with water into the urine, and increases retention of potassium ions.[20] Specifically, this process occurs in the peritubular capillaries of the kidneys in response to a change in Starling forces.[21] The inhibition of the RAAS system causes an overall decrease in blood pressure.[20]

Pharmacokinetics[edit]
Absorption[edit]
Lisinopril has a bioavailability of ~25% (reduced to 16% in people with New York Heart Association Functional Classification (NYHA) Class II–IV heart failure).[1][20] Its time to peak concentration is 7 hours.[1][20] The peak effect of lisinopril is about 4 to 8 hours after administration.[22] Food does not affect its absorption.[22]

Distribution[edit]
Lisinopril does not bind to proteins in the blood.[1][20] It does not distribute as well in people with NYHA Class II–IV heart failure.[1][20]

Metabolism[edit]
Lisinopril is the only water-soluble member of the ACE inhibitor class, with no metabolism by the liver.[22]

Elimination[edit]
Lisinopril leaves the body completely unchanged in the urine.[1][20] The half-life of lisinopril is 12 hours, and is increased in people with kidney problems.[1][20] While the plasma half-life of lisinopril has been estimated between 12 and 13 hours, the elimination half-life is much longer, at around 30 hours.[22] The full duration of action is between 24 and 30 hours.[22]

Chemistry[edit]
Pure lisinopril powder is white to off white in color.[1] Lisinopril is soluble in water (approximately 13 mg/L at room temperature),[23] less soluble in methanol, and virtually insoluble in ethanol.[1]

History[edit]
Captopril, the first ACE inhibitor, is a functional and structural analog of a peptide derived from the venom of the jararaca, a Brazilian pit viper (Bothrops jararaca).[24] Enalapril is a derivative, designed by scientists at Merck to overcome the rash and bad taste caused by captopril.[25][26]: 12–13 
Enalapril is actually a prodrug; the active metabolite is enalaprilat.[27]
Lisinopril is a synthetic peptide derivative of captopril.[23] Scientists at Merck created lisinopril by systematically altering each structural unit of enalaprilat, substituting various amino acids. Adding lysine at one end of the drug turned out to have strong activity and had adequate bioavailability when given orally; analogs of that compound resulted in lisinopril, which takes its name from the discovery with lysine.  Merck conducted clinical trials, and the drug was approved for hypertension in 1987 and congestive heart failure in 1993.[27]
The discovery posed a problem, since sales of enalapril were strong for Merck, and the company did not want to diminish those sales. Merck ended up entering into an agreement with Zeneca under which Zeneca received the right to co-market lisinopril, and Merck received the exclusive rights to an earlier stage aldose reductase inhibitor drug candidate, a potential treatment for diabetes.  Zeneca's marketing and brand name, "Zestril", turned out to be stronger than Merck's effort.[28] The drug became a blockbuster for Astrazeneca (formed in 1998), with annual sales in 1999 of $1.2B.[29]
The US patents expired in 2002.[29] Since then, lisinopril has been available under many brand names worldwide; some formulations include the diuretic hydrochlorothiazide.[5]

References[edit]
.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}

^ Jump up to: a b c d e f g h i j k l m n o p q r s t u .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}"Prinivil- lisinopril tablet". DailyMed. 4 November 2019. Retrieved 27 February 2020.

^ Jump up to: a b "Zestril- lisinopril tablet". DailyMed. 31 October 2019. Retrieved 5 August 2020.

^ Jump up to: a b "Qbrelis- lisinopril solution". DailyMed. 31 March 2020. Retrieved 5 August 2020.

^ "Dapril". Drugs.com. Drugsite Trust. Retrieved 13 August 2021.

^ Jump up to: a b "Lisinopril". Drugs.com. Retrieved 23 December 2018.

^ Jump up to: a b "Lisinopril Use During Pregnancy". Drugs.com. 22 October 2019. Retrieved 27 February 2020.

^ Jump up to: a b c d e f g h i j k l m n "Lisinopril Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 23 December 2018.

^ "Summary of Product Characteristics (SmPC) – (emc)". Lisinopril 10mg Tablet. 13 November 2019. Retrieved 27 February 2020.

^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 467. ISBN 978-3527607495.

^ "The Top 300 of 2019". ClinCalc. Retrieved 16 October 2021.

^ "Lisinopril – Drug Usage Statistics". ClinCalc. Retrieved 16 October 2021.

^ "Drug Approval Package: Qbrelis (lisinopril)". U.S. Food and Drug Administration (FDA). 29 July 2016. Retrieved 5 August 2020.

^ Sadat-Ebrahimi SR, Parnianfard N, Vahed N, Babaei H, Ghojazadeh M, Tang S, Azarpazhooh A (July 2018). "An evidence-based systematic review of the off-label uses of lisinopril". Br J Clin Pharmacol. 84 (11): 2502–21. doi:10.1111/bcp.13705. PMC 6177695. PMID 29971804.

^ Seeley A, Prynn J, Perera R, Street R, Davis D, Etyang AO (March 2020). "Pharmacotherapy for hypertension in Sub-Saharan Africa: a systematic review and network meta-analysis". BMC Med. 18 (1): 75. doi:10.1186/s12916-020-01530-z. PMC 7099775. PMID 32216794.

^ Zhang Y, He D, Zhang W, Xing Y, Guo Y, Wang F, Jia J, Yan T, Liu Y, Lin S (June 2020). "ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials". Drugs. 80 (8): 797–811. doi:10.1007/s40265-020-01290-3. PMC 7242277. PMID 32333236.

^ Mu G, Xiang Q, Zhou S, Xie Q, Liu Z, Zhang Z, Cui Y (January 2019). "Association between genetic polymorphisms and angiotensin-converting enzyme inhibitor-induced cough: a systematic review and meta-analysis". Pharmacogenomics. 20 (3): 189–212. doi:10.2217/pgs-2018-0157. PMID 30672376. S2CID 58949756.

^ "HSDB: LISINOPRIL". toxnet.nlm.nih.gov. U.S. National Library of Medicine. Retrieved 6 June 2018.

^ Dawson, AH; Harvey, D; Smith, AJ; Taylor, M; Whyte, IM; Johnson, CI; Cubela, RB; Roberts, MJ (24 February 1990). "Lisinopril overdose". Lancet. 335 (8687): 487–88. doi:10.1016/0140-6736(90)90731-j. PMID 1968218. S2CID 8480643.

^ Jump up to: a b Weinstock, Robert; Johnson, Michael (2016). "Review of Top 10 Prescribed Drugs and Their Interaction with Dental Treatment". Dental Clinics of North America. 60 (2): 421–34. doi:10.1016/j.cden.2015.11.005. PMID 27040293.

^ Jump up to: a b c d e f g h Katzung, Bertram (2012). Basic and Clinical Pharmacology. New York: McGraw Hill. pp. 175, 184–85. ISBN 978-0-07-176401-8.

^ Reddi, Alluru (2018). "Disorders of ECF Volume: Nephrotic Syndrome". Fluid, Electrolyte and Acid-Base Disorders. Springer. ISBN 978-3-319-60167-0.

^ Jump up to: a b c d e Khan, M. Gabriel (2015). "Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers". Cardiac Drug Therapy. New York: Springer. ISBN 978-1-61779-962-4.

^ Jump up to: a b "Lisinopril". PubChem. Retrieved 6 June 2018.

^ Patlak M (March 2004). "From viper's venom to drug design: treating hypertension". FASEB J. 18 (3): 421. doi:10.1096/fj.03-1398bkt. PMID 15003987. S2CID 1045315.

^ Jenny Bryan for The Pharmaceutical Journal, 17 April 2009 "From snake venom to ACE inhibitor – the discovery and rise of captopril"

^ Jie Jack Li, "History of Drug Discovery".  Chapter 1 in Drug Discovery: Practices, Processes, and Perspectives.  Eds.  Jie Jack Li, E. J. Corey. John Wiley & Sons, 2013 ISBN 978-1118354469

^ Jump up to: a b Menard J and Patchett A. "Angiotensin-Converting Enzyme Inhibitors". pp. 14–76 in Drug Discovery and Design. Volume 56 of Advances in Protein Chemistry. Eds. Richards FM, Eisenberg DS, and Kim PS. Series Ed. Scolnick EM. Academic Press, 2001. ISBN 978-0080493381. pp. 30–33

^ David R. Glover. Vie D'or: Memoirs of a Pharmaceutical Physician. Troubador Publishing Ltd, 2016. ISBN 978-1785894947. Merck Sharp and Dohme: lisinopril section

^ Jump up to: a b Express Scripts. Patent expirations


Further reading[edit]
.mw-parser-output .refbegin{font-size:90%;margin-bottom:0.5em}.mw-parser-output .refbegin-hanging-indents>ul{margin-left:0}.mw-parser-output .refbegin-hanging-indents>ul>li{margin-left:0;padding-left:3.2em;text-indent:-3.2em}.mw-parser-output .refbegin-hanging-indents ul,.mw-parser-output .refbegin-hanging-indents ul li{list-style:none}@media(max-width:720px){.mw-parser-output .refbegin-hanging-indents>ul>li{padding-left:1.6em;text-indent:-1.6em}}.mw-parser-output .refbegin-columns{margin-top:0.3em}.mw-parser-output .refbegin-columns ul{margin-top:0}.mw-parser-output .refbegin-columns li{page-break-inside:avoid;break-inside:avoid-column}
Fogari R, Zoppi A, Corradi L, Lazzari P, Mugellini A, Lusardi P (November 1998). "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients". Br J Clin Pharmacol. 46 (5): 467–71. doi:10.1046/j.1365-2125.1998.00811.x. PMC 1873694. PMID 9833600.
Bussien JP, Waeber B, Nussberger J, Gomez HJ, Brunner HR (1985). "Once-daily lisinopril in hypertensive patients: Effect on blood pressure and the renin–angiotensin system". Curr Therap Res. 37: 342–51.

External links[edit]
"Lisinopril". Drug Information Portal. U.S. National Library of Medicine.
.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}show.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}vteAntihypertensive drugs acting on the renin–angiotensin system (C09)ACE inhibitors("-pril")
Sulfhydryl-containing: Captopril
Rentiapril
Zofenopril
Dicarboxylate-containing: Enalapril#
Benazepril
Cilazapril
Delapril
Imidapril
Lisinopril (+amlodipine, +HCT)
Moexipril
Perindopril (+indapamide)
Quinapril (+HCT)
Ramipril
Spirapril
Temocapril
Trandolapril
Phosphonate-containing: Ceronapril
Fosinopril (+HCT)
Other/ungrouped: Alacepril
AIIRAs("-sartan")
Azilsartan
Candesartan
Eprosartan
Fimasartan
Irbesartan (+HCT)
Losartan (+HCT)
Olmesartan (+amlodipine, +amlodipine and HCT)
Tasosartan§
Telmisartan (+amlodipine, +HCT)
Valsartan (+amlodipine, +amlodipine and HCT, +HCT)
Renin inhibitors("-kiren")
Aliskiren (+amlodipine, +HCT, +amlodipine and HCT)
Remikiren§
Dual ACE/NEP inhibitors
Gemopatrilat
Ilepatril
Omapatrilat
Sampatrilat
Neprilysin inhibitors
Sacubitril (+valsartan)

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

showvteAngiotensin receptor modulatorsATR
Agonists: Angiotensin II
Angiotensin III
Angiotensin IV
L-163,491
Saralasin
Antagonists: Abitesartan
Azilsartan
Candesartan
Elisartan
Embusartan
Eprosartan
EXP-3174
Fimasartan
Forasartan
Irbesartan
Losartan
Milfasartan
Olmesartan
Olodanrigan
PD123319
Pomisartan
Pratosartan
Ripisartan
Saprisartan
Sparsentan
Tasosartan
Telmisartan
Valsartan
Zolasartan
ACE inhibitors: Alacepril
Benazepril
Captopril
Cilazapril
Delapril
Enalapril
Enalaprilat
Fosinopril
Gemopatrilat
Imidapril
Lisinopril
Moexipril
Omapatrilat
Perindopril
Quinapril
Quinaprilat
Ramipril
Rentiapril
Rescinnamine
Spirapril
Spiraprilat
Temocapril
Trandolapril
Zofenopril
Zofenoprilat
Renin inhibitors: Aliskiren
Ciprokiren
Ditekiren
Enalkiren
Imarikiren
Pepstatin
Remikiren
Terlakiren
Zankiren
Propeptides: Angiotensinogen
Angiotensin I
Combinations:
Amlodipine/valsartan
Olmesartan/amlodipine
Olmesartan/amlodipine/hydrochlorothiazide
Valsartan/hydrochlorothiazide
Valsartan/hydrochlorothiazide/amlodipine



.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;justify-content:center;align-items:baseline}.mw-parser-output .portal-bar-bordered{padding:0 2em;background-color:#fdfdfd;border:1px solid #a2a9b1;clear:both;margin:1em auto 0}.mw-parser-output .portal-bar-unbordered{padding:0 1.7em;margin-left:0}.mw-parser-output .portal-bar-header{margin:0 1em 0 0.5em;padding:0.2em 0;flex:0 0 auto;min-height:24px;line-height:22px}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0 1 auto;padding:0.15em 0;column-gap:1em}.mw-parser-output .portal-bar-item{display:flex;align-items:baseline;margin:0.15em 0;min-height:24px;text-align:left}.mw-parser-output .portal-bar-logo{width:22px;line-height:22px;margin:0 0.2em;text-align:right}.mw-parser-output .portal-bar-link{margin:0 0.2em;text-align:left}@media screen and (max-width:768px){.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;flex-flow:column wrap}.mw-parser-output .portal-bar-header{text-align:center;flex:0;padding-left:0.5em;margin:0 auto}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0;margin:0 auto;column-gap:1em;border-top:1px solid #a2a9b1}}.mw-parser-output .navbox+link+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .navbox+style+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .portal-bar+.navbox-styles+.navbox{margin-top:-1px}Portal:Medicine





